Probiotics, with special emphasis on their role in the management of irritable bowel syndrome

South African Journal of Clinical Nutrition

Volumn 24, Issue 2, 2011, Pages 63-73

  Stevenson, C ^a   Blaauw, R ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

IBS; Irritable bowel syndrome; Probiotics

Indexed keywords

ANTIDEPRESSANT AGENT; BULKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; PLACEBO; PROBIOTIC AGENT; SPASMOLYTIC AGENT;

ARTICLE; ATOPIC DERMATITIS; BACTEREMIA; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL (TOPIC); COLIC; COLONY FORMING UNIT; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; ENDOCARDITIS; ENTERITIS; ESCHERICHIA COLI; FUNGEMIA; HUMAN; IMMUNE RESPONSE; INFANTILE DIARRHEA; INTESTINE FLORA; INTESTINE TRANSIT TIME; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; LACTOSE INTOLERANCE; MICROBIAL COLONIZATION; MICROBIAL DIVERSITY; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS;

EID: 80054913570     PISSN: 16070658     EISSN: None     Source Type: Journal    
DOI: 10.1080/16070658.2011.11734353     Document Type: Article

References (97)

1. Metchnikoff E. The prolongation of life: optimistic studies. London: Butterworth-Heinemann; 1907.
2. Rijkers GT. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr. 2010;140:671S-76S.
3. FAO/WHO. Joint FAO/WHO expert consultation on evaluation of health and nutritional properties in food including powder milk with live lactic acid bacteria. Health and nutritional properties of probiotics in foods including powder milk with live lactic acid bacteria [homepage on the Internet]. Available from: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf
4. Sanders ME. How do we know when something called "probiotic" is really a probiotic? A guideline for consumers and health care professionals. Functional Food Rev. 2009;1:3-12.
5. Douglas LC, Sanders ME. Probiotics and prebiotics in dietetics practice. J Am Diet Assoc. 2008;108:510-521.
6. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4:430-435.
7. Abt MC, Artis D. The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis. Curr Opin Gastroenterol. 2009;25:496-502.
8. Ley RE, Peterson DA, Gordan JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837-848.
9. Chen J, Cai W, Feng Y. Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. Clin Nutr. 2007;26:559-566.
10. Conroy ME, Shi HN, Walker WA. The long-term health effects of neonatal microbial flora. Curr Opin Allergy Clin Immunol. 2009;9:197-201.
11. Taylor SN, Basile LA, Ebeling M, Wagner CL. Intestinal permeability in preterm infants by feeding type: mother's milk versus formula. Breastfeed Med. 2009;4:11-15.
12. Vael C, Desager K. The importance of the development of the intestinal microbiota in infancy. Curr Opin Pediat. 2009;21:794-800.
13. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7:503-514.
14. Brackmann S, Aamodt G, Andersen SN, et al. Widespread but not localised neoplasia in inflammatory bowel disease worsens the prognosis of colorectal cancer. Inflamm Bowel Dis. 2009;16(3):474-481.
15. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T (H) 17 cell differentiation. Nature. 2008;455(2714):808-812.
16. Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17 producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4(4):337-349.
17. Ley RE, Turnbaugh PJ. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
18. Turnbaugh PJ, Ley RE. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
19. Karin M, Lawrence T. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823-835.
20. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
21. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-693.
22. Kassinen A, Krogius-Kurikka L, Mäivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24-33.
23. Balsari A. The fecal microbial population in the irritable bowel syndrome. Microbiology. 1982;5:185-194.
24. Bayliss CE, Houstan AP. Microbiological studies on food intolerance. Proc Nutr Soc. 1984;43(1):16A.
25. Bradley HK, Wyatt GM. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol. 1987;23:29-32.
26. Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373-382.
27. Tannock GW. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol 2008;1(Suppl 1):S15-S18.
28. Swidsinski A, Loening-Baucke V, Verstraelen H, et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008;135:568-579.
29. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69:1035S-1045S.
30. Jonkers D, Stockbräger R. Review article: probiotics in gastrointestinal and liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 2):133-148.
31. Floch MH, Walker WA, Guandalini S, et al. Recommendations for probiotic use: 2008. J Clin Gastroenterol. 2008;42(Suppl 2):S104-S108.
32. Tennyson CA, Friedman G. Microecology, obesity and probiotics. Current opinion in endocrinology. Diabetes Obes. 2008;15:422-427.
33. Roberfroid M. Functional food concept and its application to prebiotics. Dig Liver Dis. 2002;34(Suppl 2):S105-S110.
34. Brouns F, Kettlitz B, Arrigoni E. Resistant starch and the butyrate revolution. Trends Food Sci Technol. 2002;13:251-261.
35. Edwards CA, Parrett AM. Intestinal flora during the first months of life: new perspectives. Br J Nutr. 2002;88(Suppl 1):S11-S18.
36. Biorivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol. 2007;23:679-692.
37. Fujiya M, Kohgo Y. Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions. Clin J Gastroenterol. 2010;3:117-127.
38. Spiller R. Review article: probiotics and prebiotcs in irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:385-396.
39. Broekaert IL, Walker WA. Probiotics and chronic disease. J Clin Gastroenterol. 2006;40:270-274.
40. Brenner DM, Moeller MJ. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009:104:1033-1049.
41. Sanders ME. Probiotics: definition, sources, selection and uses. Clin Infect Dis. 2008;46(Suppl 2):S58-S61.
42. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-1590.
43. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
44. Adams CA. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev. 2010;23(1):37-46.
45. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo controlled trial. Lancet. 2008;371:651-659.
46. Olá A, Belóyi T, Pótó L, et al. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology. 2007;54(74):590-594.
47. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr. 2010;91:687-703.
48. Boyle RJ, Robins-Browne J, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006 83:1256-1264.
49. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
50. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14(17):2650-2661.
51. Horwitz B, Fisher RS. Current concepts: the irritable bowel syndrome. N Engl J Med. 2001;344:1846-1850.
52. Verdu EF, Collins SM. Irritable bowel syndrome and probiotics: from rationale to clinical use. Curr Opin Gastroenterol. 2005;21:697-701.
53. Cabre E. Irritable bowel syndrome: can nutrient manipulation help? Curr Opin Clin Nutr Metab Care. 2010;13:581-587.
54. Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006:130:304-311.
55. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007:132:913-920.
56. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;53:281-288.
57. Harris LR, Roberts L. Treatments for irritable bowel syndrome: patients' attitudes and acceptability. BMC Complement Altern Med. 2008;19(8):65.
58. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut. 1999;45(Suppl II):1169-1177.
59. Mouyyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-332.
60. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-2222.
61. Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9:15.
62. Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2008;51(12):1775-1780.
63. Andruilli A, Neri M, Loguercio C, et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multi-center, randomized study. J Clin Gastroenterol. 2008;42(Suppl 3, Pt 2):S218-S23.
64. Bittner AC, Croffut RM, Stranahan MC. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically orientated, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther. 2005;27:755-761.
65. Zeng J, Li YQ, Zuo XL, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:994-1002.
66. Tsuchiya J, Barreto R, Okura R, et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis. 2004;5:169-174.
67. Barrett JS, Canale KE, Gearry RB, et al. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol. 2008;14:5020-5024.
68. Bausserman M, Michail S. The use of lactobacillus GG in irritable bowel syndrome in children: a doubleblind randomized controlled trial. J Pediatr. 2005;147:197-201.
69. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacilli GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25:177-184.
70. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized placebo-controlled crossover study. Digest Liv Dis. 2000;32:284-301.
71. Nobaek S, Johansson ML. Alteration of intestinal microflora associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95(5):1231-1238.
72. Niedzielin K, Kordecki H. A controlled double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-1147.
73. Sen S, Mullan MM. Effect of Lactobacillus plantarum 299V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci. 2002;47:2615-2620.
74. Kim HJ, Camilleri M, McKenzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895-904.
75. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687-696.
76. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl 6):S104-S106.
77. Kajander K, Krogius-Kurikka L. Effects of multi-species probiotc supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(3):463-473.
78. Lyra A, Krogius-Kurikka L, Nikkilä J, et al. Effect of a multi-species probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol. 2010;10:110.
79. Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multi-species probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilises intestinal microbiota. Aliment Pharmacol Ther. 2008;27:48-57.
80. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome: a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24:925-931.
81. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multi-center, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475-486.
82. Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. A double-blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008;32(2):147-152.
83. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distention and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2009;29:101-114.
84. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008;53:2714-2718.
85. Enck P, Zimmerman K, Menke G, et al. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome: a randomized controlled trial with primary care physicians. Neurogastroenterol Motil. 2008;20:1103-1109.
86. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomised controlled treatment trial of irritable bowel syndrome with a probiotic E-coli preparation (DSM17252) compared to placebo. Z Gastroenterol. 2009;47:209-14.
87. Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009;10:65-69.
88. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119-124.
89. Williams E, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29:97-103.
90. Hong KS, Kang HW, Im JP, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut and Liver. 2009;3(2):101-107.
91. Ligaarden SC, Axelsson L, Natersatd K, et al. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomized controlled trial. BMC Gastroenterol. 2010;10:16.
92. Simré M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome: a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 2010;31(2):218-227.
93. Sødergaard B, Olsson J, Ohlson K, et al. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol. 2001;46(6):663-672.
94. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomized clinical trial. Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life: a double blind, placebo controlled study. Aliment Pharmacol Ther. 2011;33(10):1123-1132.
95. Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome. J Clin Gastroenterol. 2011 [Epub ahead of print].
96. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):1143-1147.
97. Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode